Reports and Data.jpeg-01
Amoxicillin Market To Reach USD 4,962.6 Million By 2026 | Reports And Data
November 04, 2019 11:42 ET | Reports and Data
New York, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Government initiatives for the reach of amoxicillin for treating children with bacterial pneumonia, collaborations for technical advancements, and...
aad.jpg
How to Prevent Common Skin Infections at the Gym; American Academy of Dermatology
January 08, 2019 14:00 ET | American Academy of Dermatology
ROSEMONT, Ill., Jan. 08, 2019 (GLOBE NEWSWIRE) -- As more people flock to the gym for their New Year’s resolutions, dermatologists from the American Academy of Dermatology are offering words of...
Melinta Therapeutics
Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
March 02, 2017 08:00 ET | Melinta Therapeutics
NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...
Melinta Therapeutics
Melinta Therapeutics Presenting Results from Baxdela and ESKAPE Programs at ASM Microbe 2016 Meeting
June 14, 2016 12:30 ET | Melinta Therapeutics
NEW HAVEN, Conn, June 14, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that...
Melinta Therapeutics
Melinta Therapeutics’ Baxdela™ Successfully Achieves Endpoints in Confirmatory Phase 3 Study in Patients with Hospital-Treated Skin Infections
May 12, 2016 08:00 ET | Melinta Therapeutics
New Haven, CT, May 12, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, today announced top-line results...
Melinta Therapeutics
Melinta Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference
January 05, 2016 08:00 ET | Melinta Therapeutics
New Haven, CT, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that Dr. Eugene Sun, the Company’s interim Chief Executive Officer, will be providing a corporate update at...
Melinta Therapeutics
Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections
May 19, 2015 16:00 ET | Melinta Therapeutics
New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative impact of obesity on patients' recovery from acute bacterial skin and skin structure...